Ovid seeks metamorphosis into public company with $86M IPO

This follows on from a fairly quiet start to the year in terms of public offerings from biotech, although just this week Biohaven Pharmaceutical filed to raise up to $100 million in its IPO attempt to … Ovid help out on the Osaka-based company’s …
( read original story …)